| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/04/2011 | US7863299 Triazolyl derivatives of azabicyclo [3.1.0] hexane as dopamine D3 receptor modulators |
| 01/04/2011 | US7863298 1 alpha ,25-dihydroxyvitamin D3 mimetics such as 3-(4-{1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-phenyl]-propyl}-2-methylphenoxy)-propane-1,2(S)-diol, used as anticarcinogenic agents or for the treatment of glandular, urogenital, bone, skin and neurodegenreative disorders; vitamin D receptor modulators |
| 01/04/2011 | US7863297 Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes |
| 01/04/2011 | US7863296 a mixture of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and antiinsomnia drug, used for treating sleep and psychological disorders |
| 01/04/2011 | US7863295 topically administering a Glial cell-derived neurotrophic factor (GDNF) receptors agonists comprising N4-{7-chloro-2-[(E)-2-(2-chloro-phenyl)-vinyl]-quinolin-4-yl}-N1, N1-diethyl-pentane-1,4-diamine, in the form of lotions |
| 01/04/2011 | US7863294 Heterocycle derivatives as histone deacetylase (HDAC) inhibitors |
| 01/04/2011 | US7863293 Aminoalkylpyridines; treating HIV infections; antiinflammatory agents; rheumatic diseases; elevating progesator and stem cell count |
| 01/04/2011 | US7863292 modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries |
| 01/04/2011 | US7863290 drugs such as 5-(6-Chloropyridazin-3-yl)-1-azabicyclo[3.2.1]octane, used for treatment or prevention of disorders related to a nicotinic receptor dysfunction |
| 01/04/2011 | US7863289 Compounds and methods for kinase modulation, and indications therefor |
| 01/04/2011 | US7863288 protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents |
| 01/04/2011 | US7863287 Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
| 01/04/2011 | US7863286 (1R,2R,3S,4S) N4-(3-Aminocarbonylbicyclo[2.2.1]hept-5-ene-2-yl)-5-fluoro-N2-[3-(1,3-oxazol-2-yl)phenyl]-2,4-pyrimidinediamine, exhibiting antiproliferative, anticarcinogenic or antitumor activity |
| 01/04/2011 | US7863285 administering purinones such as 6-pentyl-8-(trifluoromethyl)-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-5-one, having G protein– coupled receptor agonistic acitvity, for the treatment of insulin resistance, diabetes, or metabolic syndrome |
| 01/04/2011 | US7863284 such as N-{N-{4-[N-(2-methoxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclo-penta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L- gamma -glutamyl}-D-glutamic acid, used for aiding regression and palliation of ovarian cancer; antiproliferative agents |
| 01/04/2011 | US7863283 (RS)-S-[3-({[6-Bromo-4-(isopropylamino)quinazolin-7-yl]oxy}methyl)phenyl] N-(ethoxycarbonyl)-S-ethylsulphoximide, used for the treatment of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, asthma and multiple sclerosis |
| 01/04/2011 | US7863282 Pyrimidylamino- or triazinylamino- substituted pyrazoles or 1,2,3-triazoles |
| 01/04/2011 | US7863281 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline; inhibitor of signal transduction mediated by tyrosine kinases; antitumor agent; benign prostatic hyperplasia, lungs and respiratory tract disease; bile duct |
| 01/04/2011 | US7863280 poly(ADP-ribose) polymerase (PARP) inhibitors, such as 3-(5-ethyl-2-methyl-6-oxo-1,6-dihydropyridin-3-ylamino)benzonitrile, used for the treatment of ischemia, reperfusion injuries, cardiovascular disorders or myocardium necrosis |
| 01/04/2011 | US7863279 monoacyl glycerol lipase and fatty acid amide hydrolase inhibitors such as [5-(2-chlorophenyl)[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl) piperazin-1-yl]methanone, used as analgesics or for the treatment of vomiting and nausea |
| 01/04/2011 | US7863278 Isethionate salt of a selective CDK4 inhibitor |
| 01/04/2011 | US7863277 antipsychotic (ziprasidone and quetiapine) encapsulated in cyclodextrin, and a dermatologically acceptable carrier consisting of ethoxy diglycol, lecithin soya, isopropyl palmitate, poloxamer and water; schizophrenia; Bipolar disorders |
| 01/04/2011 | US7863276 peroxisome proliferator activated receptors modulators such as (S)-4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid tosylate, used for the treatment or prevention of non-insulin dependentdiabetes, hypercholesterolemia and inflammatory disorders |
| 01/04/2011 | US7863275 Restoring gut motility by administering sepiapterin, tetrahydrobiopterin, or sex steroid hormone that increases expression and/or activity of enzymes; determining risk for diabetic gastroparesis; gastrointestinal disorders; cancer, Crohn's disease; inflammatory bowel disease, irritable bowel syndrome |
| 01/04/2011 | US7863274 phosphodiesterase inhibitors such as (6R,12aR)-6-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, used for the treatment of sexual and cardiovascular disorders |
| 01/04/2011 | US7863273 crystalline; pure dextrorotatory isomer of zopiclone( 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)-carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine); hypnotic, anxiolytic, anticonvulsant and myorelaxant; bioavailability |
| 01/04/2011 | US7863272 Therapy for stroke, cancer, multiple sclerosis, brain disorders, Parkinson's disease, Huntington's diseasee |
| 01/04/2011 | US7863271 2-aminobenzoxazole carboxamides as 5HT3 modulators |
| 01/04/2011 | US7863270 IL-12 modulatory compounds |
| 01/04/2011 | US7863269 Imino-imidazo-pyridine derivatives having antithrombotic activity |
| 01/04/2011 | US7863268 Benzothiazinone derivatives and their use as antibacterial agents |
| 01/04/2011 | US7863267 Use of selective chloride channel modulators to treat methamphetamine abuse |
| 01/04/2011 | US7863266 Therapeutic pyrazoloquinoline urea derivatives |
| 01/04/2011 | US7863265 N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[(2R or S)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-D-lysine, used as anticholesterol agents |
| 01/04/2011 | US7863264 Complex of silver and ligand; bactericides, viricides, fungicides |
| 01/04/2011 | US7863263 prostaglandin receptor agonists such as 2-[(2-{(1R,2R)-2-[(1E,4S)-4-hydroxy-7-methyl-1,7-octadien-1-yl]-5-oxocyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid, salt or cyclodextrin clathrate thereof, used as neuroprotectants or for the therapy of nervous system disorders |
| 01/04/2011 | US7863262 Nitroxyl progenitors in the treatment of heart failure |
| 01/04/2011 | US7863261 androgen receptor modulator; analogs of androst-5-ene-3 beta ,17 beta -diol ("AED") or 1,3,5(10)-estratriene-17 alpha -ethynyl-3 beta ,17 beta -diol ("EED") |
| 01/04/2011 | US7863260 for improving microcirculation in peripheral arterial occlusive disease; maintaining normovolemia; pharmacokinetic; for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases; NaCl, MgCl, KCl, CaCl2 as active ingredients |
| 01/04/2011 | US7863256 Amide derivatives of hyaluronic acid in osteoarthrosis |
| 01/04/2011 | US7863255 administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-1-(2-cyano-2-deoxy- beta -D-arabinofuranosyl)-2(1H)-pyrimidinone, or a salt, by way of continuous intravenous infusion; prolongs patient survival |
| 01/04/2011 | US7863254 Administering cytosine-containing or cytidine-containing compound, creatine- containing compound, adenosine-containing, or adenosine- elevating compound; e.g., CDP, CDP-choline, S-adenosylmethionine) or triacetyluridine |
| 01/04/2011 | US7863253 preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, a radiation-induced injury, a wound, or an inflammatory disease; purine ring with nitrile group, furan ring with two hydroxy groups and alkylamide |
| 01/04/2011 | US7863252 Chimeric oligonucleotide for use in diagnosis and treatment of tissue destruction, necrosis and inflammatory diseases |
| 01/04/2011 | US7863250 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 01/04/2011 | US7863249 Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
| 01/04/2011 | US7863248 ingesting a formualtion comprising an anthocyan e.g. glycoside of delphinidin and/or glycoside of cyanidin for alleviating spots and freckles on the skin of a subject; skin disorders; cosmetics, nutraceuticals |
| 01/04/2011 | US7863242 Compositions for down-regulation of CCR5 expression and methods of use thereof |
| 01/04/2011 | US7863047 Intracorporeal medicaments for photodynamic treatment of disease |
| 01/04/2011 | US7863029 Inhibiting multimeric porphobilinogen synthase; for use as drug, toothpaste, soap, disinfectant, anti-biofilm and herbicide |
| 01/04/2011 | US7863011 Screening at least one individual for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor |
| 01/04/2011 | US7862838 Composition and regimen for the treatment of herpes simplex and herpes zoster primarily by eliminating their pathogenetic conditions and taking into account both pathogenesis and etiology |
| 01/04/2011 | US7862836 Phosphorus binder for treatment of kidney disease |
| 01/04/2011 | US7862834 Pharmaceutical formulation comprising a water-insoluble active agent |
| 01/04/2011 | US7862833 for buccal, gingival and/or sublingual administration; effervescence acts as a penetration enhancer; pH adjusting substances |
| 01/04/2011 | US7862832 Generally linear effervescent oral fentanyl dosage form and methods of administering |
| 01/04/2011 | US7862831 Priming extracellular matrix by treating with a priming agent; adding to the primed extracellular matrix a solution of a polymerizable agent; reacting the primed extracellular matrix and polymerizable agent to create a hydrogel covalently bound to the extracellular matrix |
| 01/04/2011 | US7862818 Using chemokine specific immunoglobulin to prevent and treat inflammatory bowel disease, colitis and/or sarcoidosis |
| 01/04/2011 | US7862807 Biologically active molecule bonded to a dendrimer having a guanidine, protonated guanidine, protected guanidine, amidine, protonated amidine group, ureido, at protonated ureido group, protected ureido, a thioureido group, and a protonated thioureido goup; increasing the bioavailability of a drug |
| 01/04/2011 | US7862804 such as C-beta-D-xylopyranoside-n-propan-2-one; for hyperpigmentations caused by melanocytic hyperactivity such as melasma of forearms, idiopathic melasmas arising during pregnancy and idiopathic melasmas associated with oestrone/progestogen contraception; side effects reduction |
| 01/04/2011 | US7862800 sterilized adhesive with x-ray imagining capabilities; shelf-stable; iodo-substituted phenol (meth)acrylates as radiopaque agents; for bonding soft tissue or adheringly seal a vascular cavity |
| 01/04/2011 | US7862530 Hemodialysis without administering a systemic anticoagulant; the dialysate contains sodium citrates and potassium citrates as well as calcium and magnesium ions; increased urea clearance and pre-dialysis serum levels of bicarbonate |
| 01/04/2011 | CA2642136C Use of a pyrimidinedione derivative for preventing or treating hepatitis c |
| 01/04/2011 | CA2640591C Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 01/04/2011 | CA2627454C Hyaluronidase inhibitor containing poly-gamma-glutamic acid as an effective component |
| 01/04/2011 | CA2595782C Process for producing thiazolidinedione compound and production intermediate thereof |
| 01/04/2011 | CA2587579C Storage-stable aqueous composition comprising a magnesium compound and l-carnitine |
| 01/04/2011 | CA2577667C 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase ie |
| 01/04/2011 | CA2574926C 1,1,2,2-tetra(hetero)arylethanes or 1,1,2-tri(hetero)aryl-2-heterocyclylethanes as potassium channel inhibitors |
| 01/04/2011 | CA2558191C Composition containing benzamidine derivative and method for stabilizing benzamidine derivative |
| 01/04/2011 | CA2555591C Nitric oxide-releasing polymers |
| 01/04/2011 | CA2555331C Therapeutic agents |
| 01/04/2011 | CA2545813C The derivatives of pyridone and use thereof |
| 01/04/2011 | CA2543722C Tocopherol-modified therapeutic drug compounds |
| 01/04/2011 | CA2539986C Reduction of hair growth by applying an agonist of prostaglandin dp-receptor |
| 01/04/2011 | CA2533899C Pyridazine derivatives and their use as therapeutic agents |
| 01/04/2011 | CA2533301C 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof |
| 01/04/2011 | CA2532631C Nasal pharmaceutical composition of piribedil |
| 01/04/2011 | CA2521271C Quinoline-2-one-derivatives for the treatment of airways diseases |
| 01/04/2011 | CA2520142C Oestrogen derivatives as inhibitors of steroid sulphatase |
| 01/04/2011 | CA2517707C Decreasing the incidence of atrial fibrillation (af) in patients with left ventricular dysfunction with ace inhibitors or angiotensin ii receptor antagonists |
| 01/04/2011 | CA2513708C Formulation and methods for the treatment of thrombocythemia |
| 01/04/2011 | CA2510468C Novel 2,4-diamino-1,3,5-triazine derivative |
| 01/04/2011 | CA2507894C Use of a ppar.alpha. agonist and metformin for decreasing the serum triglycerides |
| 01/04/2011 | CA2505555C Spirocyclic cyclohexane derivatives |
| 01/04/2011 | CA2501388C Nitroaniline-based alkylating agents and their use as prodrugs |
| 01/04/2011 | CA2493995C Macrolide compounds endowed with antiinflammatory activity |
| 01/04/2011 | CA2491871C Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
| 01/04/2011 | CA2491027C Novel flavone c-glycoside derivatives and compositions containing the derivatives |
| 01/04/2011 | CA2488363C O-substituted hydroxyaryl derivatives |
| 01/04/2011 | CA2483590C Use of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy |
| 01/04/2011 | CA2481754C Antibiotic/benzoyl peroxide dispenser |
| 01/04/2011 | CA2479638C Hfa-suspension formulations of crystalline tiotropium bromide anhydrate |
| 01/04/2011 | CA2479362C N-sulfonylurea apoptosis promoters |
| 01/04/2011 | CA2474703C Therapeutic agent of glaucoma comprising bunazosin and prostaglandins |
| 01/04/2011 | CA2474343C Nsaid-containing topical formulations that demonstrate chemopreventive activity |
| 01/04/2011 | CA2474057C Integration of at least two processes to re-use acid |
| 01/04/2011 | CA2468517C Thioether substituted imidazoquinolines |
| 01/04/2011 | CA2467244C Use of cationic surfactant as antimicrobial activity enhancer in deodorants and oral care |
| 01/04/2011 | CA2465207C Pyrazole-amides and -sulfonamides |